Apimeds Pharmaceuticals US, Inc.

APUS · NYSE · SIC 2834: Pharmaceutical Preparations
28
SEC Filings

Business Summary

PART I We are a clinical stage biopharmaceutical company in the process of developing Apitox, an intradermally administered bee venom-based toxin. Our focus is primarily on developing innovative therapies that address inflammation and pain management symptoms associated with knee OA and, to a lesser extent, MS. Apitox is currently marketed and sold by Apimeds Inc. (Apimeds Korea) in South Korea as Apitoxin for the treatment of OA. Apimeds US is not associated with the market, sale and revenues g...

Next Earnings

Q2 FY2026 — expected 2026-07-15

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionAPUSdiscussed_in_filing Cybersecurity
topic_mentionAPUSdiscussed_in_filing Trusted Computing
topic_mentionAPUSdiscussed_in_filing Blockchain & Crypto
topic_mentionAPUSdiscussed_in_filing Regulation
topic_mentionAPUSdiscussed_in_filing Healthcare & Bio
topic_mentionAPUSdiscussed_in_filing Platform & Ecosystem
topic_mentionAPUSdiscussed_in_filing Cybersecurity
topic_mentionAPUSdiscussed_in_filing Trusted Computing
topic_mentionAPUSdiscussed_in_filing Blockchain & Crypto
topic_mentionAPUSdiscussed_in_filing Regulation
topic_mentionAPUSdiscussed_in_filing Healthcare & Bio
topic_mentionAPUSdiscussed_in_filing Platform & Ecosystem
topic_mentionAPUSdiscussed_in_filing Cybersecurity
topic_mentionAPUSdiscussed_in_filing Trusted Computing
topic_mentionAPUSdiscussed_in_filing Blockchain & Crypto
topic_mentionAPUSdiscussed_in_filing Regulation
topic_mentionAPUSdiscussed_in_filing Healthcare & Bio
topic_mentionAPUSdiscussed_in_filing Platform & Ecosystem
topic_mentionAPUSdiscussed_in_filing Cybersecurity
topic_mentionAPUSdiscussed_in_filing Trusted Computing

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2025-04-152024-12-310001213900-25-032206EDGAR45K words

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-122025-09-300001213900-25-109280EDGAR18K words
2025-08-192025-06-300001213900-25-078507EDGAR—
2025-05-202025-03-310001213900-25-045588EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-260001213900-26-034786EDGAR2K words
2026-03-250001213900-26-033832EDGAR—
2026-03-160001213900-26-028332EDGAR—
2026-01-020001213900-26-000464EDGAR—
2025-12-100001213900-25-119894EDGAR—
2025-12-020001213900-25-117173EDGAR—
2025-11-180001213900-25-112184EDGAR—
2025-10-160001213900-25-099553EDGAR—
2025-07-160001213900-25-064446EDGAR—
2025-06-050001213900-25-051567EDGAR—

28 total filings indexed. 14 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001894525
TickerAPUS
ExchangeNYSE
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: f171de26f69b6e0acbda1f81b05a2a29ffa677b2b8b51bdf6208d237ecf9eaeb
parent: 52d40dcf9ac6a0f31ce26765cae57214d3e2fb7e4c232d3bc47c45fda9ae4304
content hash: 79001fe7752fca804d6ca3b8cd74d804ebe179fd828a57173c352b62911a6f41
signed: 2026-04-13T04:43:41.998Z
sources: 4 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf